Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7α-hydroxylase mRNA levels

Biochemical Pharmacology

Volumn 67, Issue 2, 2004, Pages 255-267

  Williams, Kris ^a   Rao, Yi Ping ^a   Natarajan, Ramesh ^a   Pandak, W Michael ^a   Hylemon, Phillip B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid synthesis; Cholesterol; CYP7A1; Fatty acid; Indinavir; SREBP

Indexed keywords

BETA CYCLODEXTRIN; BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FATTY ACID; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INDINAVIR; MESSENGER RNA; PROTEINASE INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; CELL LEVEL; CELL NUCLEUS; CHOLESTEROL ESTERIFICATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG EFFECT; FEEDING; HALF LIFE TIME; HOMEOSTASIS; INTRACELLULAR MEMBRANE; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 1642457231     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.044     Document Type: Article

References (28)

1. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J.J., Feinberg J.E., Balfour H.H.J., Deyton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell count of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New Engl. J. Med. 337:1997;725-733.
2. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
3. Carr A., Samaras K., Chisholm K.J., Cooper D.A. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet. 351:1998;1881-1883.
4. Henry K., Huebsch J., Hermundson J., Levine C., Swenson L., Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet. 351:1998;1328-1330.
5. Manfredi R., Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42:2001;181-188.
6. Sullivan A.K., Feher M.D., Nelson M.R., Gazzard B.G. Marked hypertriglyceridemia associated with ritonavir therapy. AIDS. 12:1998;1393-1394.
7. Eschevarria K.L., Hardin T.C., Smith J.A. Hyperlipidemia associated with protease inhibitor therapy. Ann. Pharmacother. 33:1999;859-863.
8. Berthold H.K., Parhofer K.G., Ritter M.M., Addo M., Wasmuth J.C., Schliefer K., Spengler U., Rockstarh J.K. Influence of protease inhibitor therapy on lipoprotein metabolism. J. Intern. Med. 246:1999;567-575.
9. Periard D., Teleti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J., Marcovina S.M., Glauser M.P., Nicod P., Darioli R., Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 100:1999;700-705.
10. Riddle T.M., Kuhel D.G., Woollett L.A., Fichtenbaum C.J., Hui D.Y. HIV Protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissue due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276:2001;37514-37519.
11. Murata H., Hruz P.W., Muecker M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275:2000;20251-20254.
12. Zhang B., Macnaul K., Szalkowski D., Li Z., Berger J., Moller D.E. Inhibition of adipocyte differentiation by HIV protease inhibitors. J. Clin. Endocrinol. Metab. 84:1999;4274-4275.
13. Dowell P., Flexner C., Kwiterovich P.O., Lane M.D. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J. Biol. Chem. 275:2000;41325-41332.
14. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J. The HIV protease inhibitor impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation and induces insulin resistance. Diabetes. 50:2001;1378-1388.
15. Miserez A.R., Muller P.Y., Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS. 16(12):2002;1587-1594.
16. Bissell D.M., Guzelian P.S. Phenotypic stability of adult rat hepatocytes In primary monolayer culture. Ann. N.Y. Acad. Sci. 349:1980;85-98.
17. Hylemon P.B., Gurley E.C., Stravitz R.T., Litz J.S., Pandak W.M., Chiang J.Y., Vlahcevic Z.R. Hormonal regulation of cholesterol 7α-hydroxylase mRNA levels and transcriptional activity in primary rat hepatocyte cultures. J. Biol. Chem. 267:1992;16866-16871.
18. Buckley A.R., Crowe P.D., Russell D.H. Rapid activation of protein kinase C in isolated liver nuclei by prolactin, a known hepatic mitogen. Proc. Natl. Acad. Sci. U.S.A. 85:1988;8649-8653.
19. Sheng Z., Otani H., Brown M.S., Goldstein J.L. Independent regulation of sterol regulatory element-binding protein 1 and 2 in hamster liver. Proc. Natl. Acad. Sci. U.S.A. 92:1995;935-938.
20. Liscum L., Faust J.R. Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts. J. Biol. Chem. 262:1987;17002-17008.
21. Baker D.M., Wang S.-L., Bell D.J., Drevon C.A., Davis R.A. One or more labile proteins regulate the stability of chimeric mRNAs containing the 3′-untranslated region of cholesterol 7α-hydroxylase mRNA. J. Biol. Chem. 275:2000;19985-19991.
22. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:2002;1125-1131.
23. Lu T.T., Repa J.J., Mangelsdorf D.J. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J. Biol. Chem. 276:2002;37735-37738.
24. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
25. Horton J.D., Shimomura I., Brown M.S., Hammer R.E., Goldstein J.L., Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Clin. Invest. 101:1998;2331-2339.
26. Andre P., Groettrup M., Klenerman P., de Giuli R., Booth B.L. Jr., Cerundolo V., Bonneville M., Jotereau F., Zinkernagel R.M., Lotteau V. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13120-13124.
27. Fletcher C.V., Anderson P.L., Kakuda T.N., Schacher T.W., Henry K., Gross C.R., Brundage R.C. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 16:2002;551-560.
28. Chiang J.Y.L. Regulation of bile acid synthesis. Front. Biosci. 3:1998;176-193.